• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

将人工合成的人乳头瘤病毒16型mE7蛋白包裹于人乳头瘤病毒6b型L1/L2病毒样颗粒中。

Encapsidating artificial human papillomavirus-16 mE7 protein in human papillomavirus-6b L1/L2 virus like particles.

作者信息

Xu Yu-fei, Wang Qing-yong, Zhang Hong-tao, Han Ye-hua, Song Guo-xing, Xu Xue-mei

机构信息

Department of Biophysics and Structural Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, China.

出版信息

Chin Med J (Engl). 2007 Mar 20;120(6):503-8.

PMID:17439745
Abstract

BACKGROUND

Human papillomaviruses (HPVs) can infect squamous or mucosal epithelia and cause cervical cancer or genital warts. Coinfection with multiple HPV types is a common finding of many epidemiological studies. Therefore, it is necessary to develop a vaccine, which can eradicate established HPV infections and prevent other HPV infections. In this study, we generated chimeric virus like particles (cVLPs) composed of HPV-6b L1, HPV-6b L2 and one artificial HPV-16 mE7 proteins.

METHODS

The artificial HPV-16 mE7 gene was designed by codon modification, point mutation and gene shuffling then chemically synthesized and subcloned behind HPV-6b L2. HPV-6b L1 and L2-mE7 were expressed in insect cells by using Bac-to-Bac system. The generated cVLPs were purified by CsCl gradient ultracentrifuge and analyzed by immunoblot, electron microscope and haemagglutination assay.

RESULTS

The HPV-6b L1 and L2-mE7 proteins were well expressed in insect cells and could selfassemble into cVLPs, whose diameter was about 55 nm and similar to that of HPV-6b L1/L2 VLPs. Intact cVLPs could be recognized by H6.M48 neutralizing monoclonal antibody and HPV-6b L2 polyclonal antibody, while the denatured cVLPs, but not the intact cVLPs, were reactive to HPV-16 E7 polyclonal antibody. HPV-6b L1/L2-mE7 cVLPs haemagglutinated mouse erythrocytes as efficiently as HPV-6b L1/L2 VLPs did.

CONCLUSIONS

The insertion of the 158 amino acid HPV-16 mE7 protein behind L2 did not disrupt the correct assembling of cVLPs. The morphological characteristics and haemagglutinating activity of cVLPs were similar to those of HPV-6b L1/L2 VLPs. The cVLPs retained conformational B cell epitopes of HPV-6 VLPs and HPV-16 mE7 protein had an internal location in the cVLPs. Therefore, large modified E7 protein with higher immunogenicity could be incorporated into cVLPs by fusing to the C-terminus of L2, which would help to improve the therapeutic effects of L1/L2-E7 cVLPs.

摘要

背景

人乳头瘤病毒(HPV)可感染鳞状上皮或黏膜上皮,引发宫颈癌或尖锐湿疣。多种HPV类型的合并感染是许多流行病学研究中的常见发现。因此,有必要研发一种能够根除已有的HPV感染并预防其他HPV感染的疫苗。在本研究中,我们构建了由HPV-6b L1、HPV-6b L2和一种人工合成的HPV-16 mE7蛋白组成的嵌合病毒样颗粒(cVLP)。

方法

通过密码子修饰、点突变和基因改组设计人工合成的HPV-16 mE7基因,然后进行化学合成并亚克隆至HPV-6b L2基因的下游。利用杆状病毒表达系统在昆虫细胞中表达HPV-6b L1和L2-mE7。通过氯化铯梯度超速离心法纯化所产生的cVLP,并采用免疫印迹、电子显微镜和血凝试验进行分析。

结果

HPV-6b L1和L2-mE7蛋白在昆虫细胞中得到良好表达,并能自组装成cVLP,其直径约为55 nm,与HPV-6b L1/L2 VLP相似。完整的cVLP可被H6.M48中和单克隆抗体和HPV-6b L2多克隆抗体识别,而变性的cVLP(而非完整的cVLP)可与HPV-16 E7多克隆抗体发生反应。HPV-6b L1/L2-mE7 cVLP凝集小鼠红细胞的效率与HPV-6b L1/L2 VLP相同。

结论

在L2蛋白的下游插入158个氨基酸的HPV-16 mE7蛋白并不影响cVLP的正确组装。cVLP的形态特征和血凝活性与HPV-6b L1/L2 VLP相似。cVLP保留了HPV-6 VLP的构象性B细胞表位,且HPV-16 mE7蛋白位于cVLP的内部。因此,通过与L2的C末端融合,具有更高免疫原性的大型修饰E7蛋白可被整合到cVLP中,这将有助于提高L1/L2-E7 cVLP的治疗效果。

相似文献

1
Encapsidating artificial human papillomavirus-16 mE7 protein in human papillomavirus-6b L1/L2 virus like particles.将人工合成的人乳头瘤病毒16型mE7蛋白包裹于人乳头瘤病毒6b型L1/L2病毒样颗粒中。
Chin Med J (Engl). 2007 Mar 20;120(6):503-8.
2
Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention.16型人乳头瘤病毒L1嵌合病毒样颗粒与L1/L2嵌合病毒样颗粒在肿瘤预防中的比较
Intervirology. 2002;45(4-6):300-7. doi: 10.1159/000067921.
3
Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.由L1/L2嵌合病毒样颗粒组成的人乳头瘤病毒疫苗在临床前模型中诱导产生广泛的交叉保护作用。
J Virol. 2016 Jun 24;90(14):6314-25. doi: 10.1128/JVI.00449-16. Print 2016 Jul 15.
4
Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model.用含有 HPV-16 E6 和 E7 表位的 HPV-16 L1 嵌合病毒样颗粒免疫可在 HPV-16 肿瘤小鼠模型中产生持久的预防和治疗效果。
Arch Virol. 2014 Feb;159(2):291-305. doi: 10.1007/s00705-013-1819-z. Epub 2013 Aug 29.
5
Enhancement of vaccine potency by fusing modified LTK63 into human papillomavirus type 16 chimeric virus-like particles.通过将修饰的LTK63融合到人乳头瘤病毒16型嵌合病毒样颗粒中来增强疫苗效力。
FEMS Immunol Med Microbiol. 2008 Jan;52(1):99-109. doi: 10.1111/j.1574-695X.2007.00339.x. Epub 2007 Nov 7.
6
Activation of dendritic cells and induction of T cell responses by HPV 16 L1/E7 chimeric virus-like particles are enhanced by CpG ODN or sorbitol.CpG ODN或山梨醇可增强人乳头瘤病毒16型L1/E7嵌合病毒样颗粒对树突状细胞的激活及T细胞反应的诱导。
Antivir Ther. 2004 Aug;9(4):479-89.
7
VLP Production from Recombinant L1/L2 HPV-16 Protein Expressed in Pichia Pastoris.在毕赤酵母中表达的重组L1/L2人乳头瘤病毒16型蛋白生产病毒样颗粒
Protein Pept Lett. 2018;25(8):783-790. doi: 10.2174/0929866525666180809124633.
8
Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16.呈现人乳头瘤病毒6型(HPV-6)和人乳头瘤病毒16型(HPV-16)次要衣壳蛋白L2共同中和表位的嵌合人乳头瘤病毒16型(HPV-16)L1颗粒。
J Virol. 2003 Aug;77(15):8386-93. doi: 10.1128/jvi.77.15.8386-8393.2003.
9
Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.次要衣壳蛋白L2多表位诱导针对致癌性和黏膜型人乳头瘤病毒的广泛保护。
J Virol. 2018 Jan 30;92(4). doi: 10.1128/JVI.01930-17. Print 2018 Feb 15.
10
Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.串联多类型L2融合蛋白作为候选预防性全人乳头瘤病毒疫苗
J Natl Cancer Inst. 2009 Jun 3;101(11):782-92. doi: 10.1093/jnci/djp106. Epub 2009 May 26.

引用本文的文献

1
A safe and potentiated multi-type HPV L2-E7 nanoparticle vaccine with combined prophylactic and therapeutic activity.一种具有联合预防和治疗活性的安全且增强型多类型HPV L2-E7纳米颗粒疫苗。
NPJ Vaccines. 2024 Jun 26;9(1):119. doi: 10.1038/s41541-024-00914-z.
2
The Magic Staff: A Comprehensive Overview of Baculovirus-Based Technologies Applied to Human and Animal Health.《魔棒:杆状病毒技术在人类和动物健康中的综合应用概述》
Viruses. 2022 Dec 28;15(1):80. doi: 10.3390/v15010080.
3
Combined prophylactic and therapeutic immune responses against human papillomaviruses induced by a thioredoxin-based L2-E7 nanoparticle vaccine.
基于硫氧还蛋白的 L2-E7 纳米颗粒疫苗诱导针对人乳头瘤病毒的联合预防和治疗性免疫反应。
PLoS Pathog. 2020 Sep 4;16(9):e1008827. doi: 10.1371/journal.ppat.1008827. eCollection 2020 Sep.